發(fā)布時(shí)間：2019-01-04 13:33

【摘要】：原發(fā)漿細(xì)胞白血病(primary plasma cell leukemia,PPCL)屬于高度侵襲性的漿細(xì)胞疾病。與多發(fā)性骨髓瘤相比,PPCL有其獨(dú)特的細(xì)胞遺傳學(xué)及分子生物學(xué)特征�；�,新藥如硼替佐米,免疫調(diào)節(jié)劑及造血干細(xì)胞移植的聯(lián)合應(yīng)用提高了PPCL患者的預(yù)后和生存,而不同的遺傳及基因表達(dá)譜亦與不同預(yù)后相關(guān)。處于臨床試驗(yàn)階段的部分靶向藥物如CD38單克隆抗體和CD138-CAR-T等也為PPCL的治療提供了新的方向。本文就近年來(lái)PPCL的診斷和治療的最新進(jìn)展作一綜述,討論的主要問(wèn)題包括有PPCL的診斷,PPCL的臨床及生化特征,PPCL的治療及預(yù)后和PPCL新藥研究現(xiàn)狀等。
[Abstract]:Primary plasmacytic leukemia (primary plasma cell leukemia,PPCL) is a highly invasive plasmacytic disease. Compared with multiple myeloma, PPCL has its unique cytogenetic and molecular biological characteristics. The combination of chemotherapy, new drugs such as bortezomil, immunomodulator and hematopoietic stem cell transplantation improved the prognosis and survival of PPCL patients, and different genetic and gene expression profiles were also associated with different prognosis. Some targeted drugs, such as CD38 monoclonal antibody and CD138-CAR-T, also provide a new direction for the treatment of PPCL. This paper reviews the recent advances in the diagnosis and treatment of PPCL. The main issues discussed include the diagnosis of PPCL, the clinical and biochemical characteristics of PPCL, the treatment and prognosis of PPCL, and the current status of new PPCL drugs.
【作者單位】： 南京醫(yī)科大學(xué)附屬無(wú)錫市人民醫(yī)院血液科;南京醫(yī)科大學(xué)第一附屬醫(yī)院血液科;
【分類號(hào)】：R733.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 余九華;張達(dá);;肝臟炎性假瘤一例誤診分析[J];臨床誤診誤治;2006年12期

2 何庭艷;馮賢松;;肝濾泡樹突細(xì)胞肉瘤一例報(bào)告并文獻(xiàn)復(fù)習(xí)[J];腹部外科;2010年06期

3 馬泓智;房居高;王琪;;鼻及鼻竇炎性肌纖維母細(xì)胞瘤[J];中國(guó)耳鼻咽喉頭頸外科;2009年04期

4 赫淑倩,周巧蓮;腎臟炎性假瘤23例報(bào)告[J];菏澤醫(yī)專學(xué)報(bào);2000年04期

，

本文編號(hào)：2400357